Recent advances in hepatic transplantation at the University of Pittsburgh.
- 1 January 1993
- journal article
- p. 137-52
Abstract
FK506 undoubtedly improved the survival advantage of hepatic allotransplantation. Hepatic-intestinal and multivisceral transplantation has also become a feasible therapy for patients with combined intestinal and liver failure. With better understanding of the immunologic and metabolic aspects of allo- and xenotransplantation, further clinical attempts to transplant animal organs to humans may be considered with the hope for a better outcome in the very near future.This publication has 48 references indexed in Scilit:
- LIVER TRANSPLANTATION IN POSITIVE CYTOTOXIC CROSSMATCH CASES USING FK506, HIGH-DOSE STEROIDS, AND PROSTAGLANDIN ETransplantation, 1992
- A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.1991
- Infectious complications of pediatric liver transplantation under FK 506.1991
- THE EFFECT OF GRAFT FUNCTION ON FK506 PLASMA LEVELS, DOSAGES, AND RENAL FUNCTION, WITH PARTICULAR REFERENCE TO THE LIVERTransplantation, 1991
- Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.1991
- Liver transplantation under cyclosporine: a decade of experience.1991
- Infections in adult liver transplant patients under FK 506 immunosuppression.1991
- Pharmacokinetics of FK 506: preclinical and clinical studies.1990
- Second International Workshop on FK 506. A potential breakthrough in immunosuppression: clinical implications. October 31, 1989, Barcelona, Spain. Proceedings.1990
- ‘Actively Acquired Tolerance’ of Foreign CellsNature, 1953